IP Library Granted Patent US 12,083,085
Granted Patent B2
US 12,083,085 · App. 17/855,072 · Granted Sep 10, 2024

Antiseptic, antiseborrheic, exfoliating composition to remove or prevent acne

Inventors: José Agustín Rogelio Magaña Castro (Mexico City, MX); Laura Vázquez Cervantes (Mexico City, MX); Pedro Peña Santoyo (Mexico City, MX)
Assignee: Excalibur Pharmaceuticals, Inc.
A61K31/191A61K8/365A61K8/46A61K31/10A61Q17/005A61Q19/008A61Q19/10A61K2800/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,083,085
App. No.
17/855,072
Granted
Sep 10, 2024
Kind
B2
Abstract

The invention refers to an antimicrobial, exfoliating and seboregulating hydrosoluble composition comprising a combination of diallyl disulphide modified oxide (DDMO) and alpha hydroxyethanoic acid (glycolic acid), which acts removing bacteria affecting the skin including those caused by acne, said composition also provides deep cleansing, exfoliating action, reduces epidermal cohesion facilitating cellular change, preventing the occurrence of several forms of acne in the skin and additionally producing seboregulating effects by avoiding blockage of sebaceous glands.

Claims (47)

1. A method for removing skin microbes from the skin of a subject in need thereof, the method comprising administering a composition to the skin of the subject, wherein the microbes are bacteria and/or fungi, and wherein the composition comprises from 0.001 to 10% by weight of diallyl disulfide modified oxide, from 1 to 12% by weight of glycolic acid, from 0.3 to 24% by weight of one or more surfactants, from 0.3 to 10% by weight of a moisturizing agent, from 0.2 to 10% by weight of an aromatizing agent, and from 40 to 70% by weight of an aqueous solvent.

2. The method according to claim 1 , wherein the one or more surfactants are selected from the group consisting of alkylbenzensulfates and ionic alkyl sulfates.

3. The method according to claim 1 , wherein the one or more surfactants are selected from the group consisting of sodium lauryl sulfate, sodium lauryl ether sulfate, and ammonium lauryl sulfate.

4. The method according to claim 1 , wherein the moisturizing agent is selected from the group consisting of ethylene glycol, propylene glycol, glycerin, sorbitol, polyoxyethylated glycerols, and polyoxyethylated sugars.

5. The method according to claim 1 , wherein the aqueous solvent is selected from water and water-hydrosoluble alcohol mixtures.

6. The method according to claim 1 , wherein the composition comprises:

a) 0.8% by weight diallyl disulfide modified oxide;

b) 11.42% by weight glycolic acid;

c) 10% by weight sodium lauryl sulfate;

d) 10% by weight sodium lauryl ether sulfate;

e) 0.5% by weight glycerin; and

f) 66.68% by weight water.

7. The method according to claim 1 , wherein the composition comprises:

a) 1% by weight diallyl disulfide modified oxide;

b) 11.6% by weight glycolic acid;

c) 8% by weight sodium lauryl sulfate;

d) 12% by weight sodium lauryl ether sulfate;

e) 0.5% by weight ethylene glycol; and

f) 66.3% by weight water.

8. The method according to claim 1 , wherein the composition comprises:

a) 0.8% by weight diallyl disulfide modified oxide;

b) 11.42% by weight glycolic acid;

c) 20% by weight sodium lauryl ether sulfate;

d) 0.4% by weight sorbitol; and

e) 66.78% by weight water.

9. The method according to claim 1 , wherein the microbes are bacteria.

10. The method according to claim 9 , wherein the bacteria are Gram-negative bacteria or Gram-positive bacteria.

11. The method according to claim 9 , wherein the bacteria are Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Proteus vulgaris, Staphylococcus aureus, Staphylococcus epidermidis, Propionibacterium acnes , or a combination thereof.

12. The method according to claim 1 , wherein the microbes are fungi.

13. The method according to claim 12 , wherein the fungus is Candida albicans.

14. A method for killing bacteria or fungi on a skin of a subject in need thereof, the method comprising administering a composition to the skin of the subject, wherein the composition comprises:

a) diallyl disulfide modified oxide;

b) glycolic acid;

c) a surfactant selected from the group consisting of (i) sodium lauryl sulfate, (ii) sodium lauryl ether sulfate, and (iii) sodium lauryl sulfate and sodium lauryl ether sulfate; and

d) a moisturizing agent selected from the group consisting of glycerin, ethylene glycol, and sorbitol.

15. The method according to claim 14 , wherein the diallyl disulfide modified oxide is 0.8% or 1.0% by weight of the composition.

16. The method according to claim 14 , wherein the moisturizing agent is glycerin.

17. The method according to claim 14 , wherein the surfactant is 20% by weight of the composition.

18. The method according to claim 14 , wherein the moisturizing agent is 0.4% or 0.5% by weight of the composition.

19. The method according to claim 14 , wherein the glycolic acid is 11.42% by weight or 11.6% by weight of the composition.

20. A method for removing grease or oil from a skin of a subject in need thereof, the method comprising administering a composition to the skin of the subject, wherein the composition comprises:

a) from 0.001 to 10% by weight of diallyl disulfide modified oxide;

b) from 1 to 12% by weight of glycolic acid;

c) from 0.3 to 24% by weight of one or more surfactants;

d) from 0.3 to 10% by weight of a moisturizing agent;

e) from 0.2 to 10% by weight of an aromatizing agent; and

f) from 40 to 70% by weight of an aqueous solvent.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2023
From: GRUPO MEDIFARMA S.A. DE C.V.
To: EXCALIBUR PHARMACEUTICALS, INC.
Reel/Frame 062390/0701 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRESPONDENCE STREET ADDRESS PREVIOUSLY RECORDED AT REEL: 061587 FRAME: 0367. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jan 9, 2023
From: MAGAÑA CASTRO, JOSÉ AGUSTÍN ROGELIO; CERVANTES, LAURA VÁZQUEZ; SANTOYO, PEDRO PEÑA
To: GRUPO MEDIFARMA S.A. DE C.V.
Reel/Frame 062335/0246 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2022
From: MAGAÑA CASTRO, JOSÉ AGUSTÍN ROGELIO; CERVANTES, LAURA VÁZQUEZ; SANTOYO, PEDRO PEÑA
To: GRUPO MEDIFARMA S.A. DE C.V.
Reel/Frame 061587/0367 →
Priority Claims (1)
MX MX/a/2012/009806 · Aug 23, 2012 · national
Continuity (5)
Continuation 17063458 · Oct 5, 2020
Continuation 16371670 · Apr 1, 2019
Continuation 16008210 · Jun 14, 2018
Continuation 14421616
Related Publication 20230165819A1 · Jun 1, 2023
Cited By (2)
US 12,667,561 US 12,702,713